<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322475</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 Rejuvenation-17-02</org_study_id>
    <nct_id>NCT03322475</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of at least 20 healthy subjects at a single site, with at least two facial sub-areas
      with visible wrinkles with pigmentation and/or acne scars who wish to improve their skin
      appearance will be enrolled into the study. subjects will receive 3 treatments and return to
      follow-up visits at 1, 3, and 6 months following the last treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fitzpatrick Elastosis Score (FES) scale</measure>
    <time_frame>Baseline, 1 month follow up</time_frame>
    <description>Fine lines/wrinkles and elastosis improvement will be classified by the Fitzpatrick-Goldman Elastosis and Wrinkles scales: Class I, Class II or Class III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Global Aesthetic Improvement (GAI) Scale</measure>
    <time_frame>Baseline, 1 month follow up</time_frame>
    <description>The global aesthetic improvement (GAI) scale will be used by the investigator to grade improvement in the following categories: 1) Fine lines/wrinkles; 2) texture 3) Pigmentation 4) Acne scars. Score 0-Worse, Score 1-No Change, Score 2- Somewhat improved, Score 3- Moderately improved, Score 4-Very Much Improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fitzpatrick Elastosis Score (FES) scale</measure>
    <time_frame>Baseline, 3 month follow up</time_frame>
    <description>Skin improvement on the FES scale will be classified by the Fitzpatrick-Goldman Elastosis and Wrinkles scales at the 3 month-follow-up visits as compared to baseline.
Classification: Class I, Class II or Class III.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Skin Rejuvenation</condition>
  <arm_group>
    <arm_group_label>Facial skin rejuvenation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facial skin rejuvenation using PiQo4 laser system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4 laser system</intervention_name>
    <description>The PiQo4 laser system</description>
    <arm_group_label>Facial skin rejuvenation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to be entered into the study:

          -  Healthy Female/Male.

          -  Age= 18-70 (Adults).

          -  Fitzpatrick skin phototype = I-V

          -  Exhibiting at least two facial sub-areas with visible wrinkles with pigmentation
             and/or acne scars.

          -  Able to read, understand and provide written Informed Consent.

          -  Able and willing to comply with the treatment/follow-up schedule and post treatment
             care

          -  Willingness to provide a brief medical history including disclosure of any prescribed
             or over-the-counter medications taken within the past 6 months.

          -  Willingness to allow Focus Medical (the study Sponsor) and Lumenis and the
             investigators to use de-identified photographs of the treated area for presentation
             and publication purposes.

          -  Daily use of sunscreen for the duration of the study

          -  Women of child-bearing potential are required to use a reliable method of birth
             control (such as an intrauterine device, birth control pills, condom with spermicidal,
             NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or
             abstinence) during the course of the study.

        Exclusion Criteria:

        Any of the following will exclude the subject from the study:

          -  Pregnant, intending to become pregnant during the course of study, less than 3 months
             postpartum or less than 3 months after completion of breastfeeding

          -  Prior skin laser, light or other energy device treatment in treated area within 6
             months of initial treatment or during the course of the study.

          -  Known hypersensitivity or contraindications to anesthetic agents including lidocaine
             and its derivatives, and Toradol.

          -  Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in
             the treated area, unless treatment is conducted following a prophylactic regimen.

          -  History of post inflammatory pigmentary disorders, particularly a tendency for hyper-
             or hypo-pigmentation.

          -  Having Melasma.

          -  Having multiple dysplastic Nevi in are to be treated.

          -  Having an excessive underlying vascular conditions (e.g. dense network of
             capillaries).

          -  History of keloid scarring or of abnormal wound healing.

          -  Suffering from current or history of significant skin conditions in the treated area
             or inflammatory skin conditions.

          -  History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or currently using immunosuppressive medications.

          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation
             medications one week prior to and during the treatment course (to allow inclusion,
             temporary cessation of use as per the subject's physician's discretion).

          -  Having a neurological disorder (including Multiple Sclerosis, Parkinson's disease).

          -  Having seizure disorder.

          -  Having fibromyalgia.

          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study.

          -  Participation in a study of another device or drug within three months prior to
             enrolment or during the study.

          -  Significant concurrent illness (e.g. uncontrolled diabetes) or any disease state that
             in the opinion of the Investigator would interfere with the treatment or healing
             process

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.

          -  Subjects who are opposed to possible damage to the hair follicles with possible loss
             of hair in the treatment area.

          -  Received the following treatments in the area of the face to be treated during or
             within the noted timeframes prior to the study treatment:

               1. Dermabrasion or chemical peel treatment within 3 months.

               2. Any devices and/or Botox treatment within 6 months.

               3. Collagen/fat injections or other methods of augmentation with injected or
                  implanted material in the treated area within 9 months.

               4. Resurfacing procedure, face lift or eyelid surgery within a year.

               5. Having a permanent implant in the facial skin area, such as an injected chemical
                  substance.

               6. Any other surgery in treated area within 9 months of initial treatment or during
                  the course of the study

               7. Use of retinoids, antioxidants or therapeutic skin nourishing supplements at
                  medicinal concentration within 2 months and oral retinoids within 6 months of the
                  study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edward Ross, MD</last_name>
    <phone>(858) 764-3023</phone>
    <email>Buchanan.tiffany@scrippshealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany Buchanan</last_name>
    <phone>(858) 764-3023</phone>
    <email>Buchanan.tiffany@scrippshealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Clinical Research Services</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

